GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

Noninvasive monitoring and evaluation of anti-tumor responses as a predictive tool

$191,276
Mohammad Rashidian · Dana-Farber Cancer Inst · K22 · FY2020 · CA

Noninvasive monitoring and evaluation of anti-tumor responses as a predictive tool

$191,276
Mohammad Rashidian · Dana-Farber Cancer Inst · K22 · FY2021 · CA

Novel small-molecule inhibitors of Wee1 kinase for medulloblastoma treatment

$191,193
Philip Reigan · University Of Colorado Denver · R21 · FY2014 · NS

NCI-Alliance immune-related Adverse Events (irAE) Biorepository-Cures

$191,131
James L. Gulley · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Role of human endogenous retroviruses in tumor immunity of ovarian carcinoma

$191,044
Katherine B Chiappinelli · George Washington University · R21 · FY2018 · CA

Designer EcN for treatment of solid tumors

$190,994
Cammie Lesser · Massachusetts General Hospital · R21 · FY2023 · CA

Understanding how mitotic kinases drive EMT in breast cancers

$190,408
Srikumar P Chellappan · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2019 · CA

PVSRIPO in melanoma

$190,389
Georgia Beasley · Duke University · K08 · FY2023 · CA

Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy

$190,217
Tanaya Shree · Oregon Health & Science University · K08 · FY2022 · CA

Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy

$190,217
Tanaya Shree · Oregon Health & Science University · K08 · FY2024 · CA

Dynamic Analysis of Tumor and Microenvironment in Patients Undergoing Immunotherapy

$190,177
Tanaya Shree · Oregon Health & Science University · K08 · FY2023 · CA

Mkp-1 suppresses immune checkpoint protein PD-L1 to prevent sepsis-associated immune dysfunction and mortality

$190,000
Yusen Liu · Research Inst Nationwide Children'S Hosp · R21 · FY2020 · AI

First in Human Trials of ProAgio, a Cytotoxin

$189,995
Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA

CYTOKINE SIGNALING PATHWAYS REGULATING A G1 CHECKPOINT

$189,728
University Of Iowa · R01 · FY2000 · CA

Targeting Ribosomal Biogenesis in Prostate Cancer

$189,681
Everardo Macias · Cedars-Sinai Medical Center · K22 · FY2016 · CA

Discovery of PD-1/PDL-1 inhibitors from marine microbial natural products

$189,600
William Fenical · University Of California, San Diego · R01 · FY2021 · CA

Airway Immune Response in Critically Ill Children-Precision Medicine in Children At Risk for Acute Respiratory Distress Syndrome

$189,485
Jocelyn Rebecca Grunwell · Emory University · K23 · FY2022 · HL

A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy

$189,338
Wantong Yao · University Of Tx Md Anderson Can Ctr · R21 · FY2025 · CA

Liposome-based mRNA cancer immunotherapy targeting ion channels

$189,338
Laura Conforti · University Of Cincinnati · R21 · FY2023 · CA

Dissecting drug resistance in serial uveal melanoma biopsies using integrated, multi-modal single-cell profiling and novel machine learning tools.

$189,338
Benjamin Izar · Columbia University Health Sciences · R21 · FY2021 · CA

Elucidating the role of tumor cell-intrinsic hypoxia inducible factor (HIF)-1α and HIF-2α pathway activation in tumor immune evasion

$189,195
Jonathan A Trujillo · University Of Chicago · K08 · FY2025 · CA

Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids

$189,130
Russell William Jenkins · Massachusetts General Hospital · K08 · FY2019 · CA

Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids

$189,130
Russell William Jenkins · Massachusetts General Hospital · K08 · FY2020 · CA

Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids

$189,130
Russell William Jenkins · Massachusetts General Hospital · K08 · FY2022 · CA

Ex Vivo Profiling of Immunotherapy Combinations Using Organotypic Tumor Spheroids

$189,130
Russell William Jenkins · Massachusetts General Hospital · K08 · FY2018 · CA